IR – Press Release 2017-10-27: Zynex Growth Leads to a New Corporate Headquarters

October 27, 2017

Zynex Growth Leads to a New Corporate Headquarters

LONE TREE, Colo., October 27, 2017 /PRNEWSWIRE/ — Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it has leased new office space and will be moving its corporate headquarters to 9555 Maroon Circle, Englewood CO 80112.

The new building is less than one mile from the existing headquarters and will expand the footprint from approximately 17,000 square feet to approximately 43,800 square feet with a first right of refusal to occupy additional space in the building. An 8-K has been filed with the details of the lease arrangements. The lease is for sixty-six months and can be extended by another two years until June 30, 2025.

Thomas Sandgaard, CEO said: “Our recent growth has made it necessary for us to lease larger office and manufacturing space to accommodate not only a higher level of activity as well as anticipated future growth. We continue to outsource many functions, such as electronic assembly, in an effort to have as much flexibility in our growth as possible. We expect to move into the new space in January 2017.”

About Zynex

Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company’s proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit:

Safe Harbor Statement

Certain statements in this release are “forward-looking” and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or augment our liquidity in order to continue our business, the success of our international expansion efforts, our ability to engage additional sales representatives and their success, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation, our ability to up-list to a larger exchange and other risks described in our filings with the Securities and Exchange Commission including the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2016 as well as Forms 10-Q, 8-K and 8-K/A, press releases and the Company’s website.

Zynex, Inc.
(303) 703-4906

Investor Relations Contact:
Amato And Partners, LLC
Investor Relations Counsel
[email protected]

To view the original version on PR Newswire, visit:

Copyright (C) 2017 PR Newswire. All rights reserved